• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Transient Ischemic Attack Market Research Report - Global Forecast till 2032 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Transient Ischemic Attack Market

    ID: MRFR/Pharma/3590-CR
    226 Pages
    Rahul Gotadki
    July 2019

    Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Transient Ischemic Attack Market Research Report - Global Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Transient Ischemic Attack Market Summary

    The Global Transient Ischemic Attack Market is projected to grow from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035.

    Key Market Trends & Highlights

    Transient Ischemic Attack Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 11.0% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 0.38 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 0.12 USD Billion, reflecting the current demand for TIA management solutions.
    • Growing adoption of advanced diagnostic technologies due to increasing awareness of transient ischemic attacks is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.12 (USD Billion)
    2035 Market Size 0.38 (USD Billion)
    CAGR (2025-2035) 11.0%

    Major Players

    Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), Boehringer Ingelheim GmbH (Germany)

    Transient Ischemic Attack Market Trends

    The increasing prevalence of transient ischemic attacks underscores the urgent need for enhanced preventive strategies and effective treatment options to mitigate long-term neurological damage.

    Centers for Disease Control and Prevention (CDC)

    Transient Ischemic Attack Market Drivers

    Aging Population

    The demographic shift towards an aging population is a crucial factor driving the Global Transient Ischemic Attack Market Industry. As individuals age, the risk of cerebrovascular diseases, including TIAs, escalates. The United Nations projects that by 2030, the global population aged 60 years and older will reach 1.4 billion, creating a larger cohort susceptible to TIAs. This demographic trend necessitates enhanced healthcare services and interventions tailored to older adults, thereby fostering market expansion. The increasing burden of TIAs among the elderly population underscores the importance of developing targeted therapies and preventive measures.

    Rising Incidence of Stroke

    The increasing prevalence of stroke globally is a pivotal driver for the Global Transient Ischemic Attack Market Industry. As per recent health statistics, stroke remains one of the leading causes of morbidity and mortality worldwide. The World Health Organization indicates that approximately 15 million people suffer from stroke annually, with a significant portion experiencing transient ischemic attacks as precursors. This alarming trend underscores the necessity for enhanced diagnostic and therapeutic interventions, thereby propelling market growth. The Global Transient Ischemic Attack Market is projected to reach 0.12 USD Billion in 2024, reflecting the urgent need for effective management strategies.

    Market Trends and Projections

    The Global Transient Ischemic Attack Market Industry is witnessing notable trends that indicate a robust growth trajectory. Projections suggest that the market will expand from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035, reflecting a compound annual growth rate of 11.0% from 2025 to 2035. This growth is driven by various factors, including advancements in medical technology, increased awareness, and an aging population. The market dynamics are influenced by the evolving healthcare landscape, necessitating continuous adaptation by stakeholders to meet the demands of TIA management.

    Regulatory Support and Funding

    Government initiatives and regulatory support play a vital role in shaping the Global Transient Ischemic Attack Market Industry. Various health authorities are implementing policies aimed at improving stroke care and funding research for innovative treatments. For example, the National Institutes of Health in the United States allocates substantial resources to stroke research, which indirectly benefits TIA management. Such funding encourages the development of new therapies and technologies, thereby enhancing patient care. This supportive regulatory environment is expected to facilitate market growth, as stakeholders are more inclined to invest in TIA-related innovations.

    Increased Awareness and Education

    Growing awareness regarding transient ischemic attacks and their implications is significantly influencing the Global Transient Ischemic Attack Market Industry. Public health campaigns and educational initiatives by health organizations aim to inform individuals about the symptoms and risks associated with TIAs. This heightened awareness encourages early medical intervention, which is essential for preventing subsequent strokes. As a result, healthcare systems are increasingly prioritizing TIA management, leading to a surge in demand for related services and products. The market is expected to experience a compound annual growth rate of 11.0% from 2025 to 2035, driven by these educational efforts.

    Advancements in Medical Technology

    Technological innovations in medical devices and diagnostic tools are transforming the landscape of the Global Transient Ischemic Attack Market Industry. The advent of portable imaging technologies and telemedicine solutions facilitates timely diagnosis and treatment, which is crucial for TIA patients. For instance, advanced MRI techniques enable rapid identification of ischemic episodes, thereby improving patient outcomes. Furthermore, the integration of artificial intelligence in predictive analytics is enhancing risk stratification for TIA patients. These advancements not only improve clinical efficacy but also contribute to the anticipated market growth, with projections indicating a rise to 0.38 USD Billion by 2035.

    Market Segment Insights

    Regional Insights

    Key Companies in the Transient Ischemic Attack Market market include

    Industry Developments

    Future Outlook

    Transient Ischemic Attack Market Future Outlook

    The Global Transient Ischemic Attack Market is projected to grow at an 11.0% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing awareness, and enhanced treatment options.

    New opportunities lie in:

    • Develop AI-driven diagnostic tools to improve early detection of TIAs.
    • Invest in telehealth solutions for remote monitoring and patient management.
    • Create targeted therapies focusing on high-risk populations to enhance treatment efficacy.

    By 2035, the market is expected to achieve substantial growth, reflecting advancements in treatment and increased patient engagement.

    Market Segmentation

    Market Segmentation

    Transient Ischemic Attack Market, by Region
    • Americas
    • North America
    • US
    • Canada
    • Latin America
    • Europe
    • Western Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    Transient Ischemic Attack Market, by End-User
    • Hospitals & Clinics
    • Diagnostic Centers
    • Research Laboratories
    Transient Ischemic Attack Market, by Diagnosis
    • Imaging Techniques
    • Computed Tomography (CT) scan
    • Carotid Duplex Scanning
    • Magnetic Resonance Imaging
    • Echocardiography            
    Transient Ischemic Attack Market, by Treatment
    • Surgery
    • Drugs
    • Antithrombotic agents
    • Antiplatelets
    • Clopidogrel
    • Aspirin
    • Heparins
    • ENOXAPARIN
    • DALTEPARIN
    • Fibrinolytics
    • Tenecteplase
    Transient Ischemic Attack Market, by Age Groups
    • 0–18 years
    • 19–40 years (Millennial)
    • 41–60 years
    • 60+ years

    Report Scope

    Attribute/Metric Details
    Market Size 2030  USD 0.29 Billion 2032
    Compound Annual Growth Rate (CAGR) 9.34% 2032
    Base Year 2021
    Market Forecast Period 2024-2032
    Historical Data 2018 - 2021
    Market Forecast Units Value (USD Million)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, technology, application, and end-users.
    Geographies Covered Americas, Europe, Asia Pacific and the Middle East and Africa
    Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
    Key Companies Profiled Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).
    Key Market Opportunities Key market opportunities for the Transient Ischemic Attack market include the development of advanced diagnostic tools, innovative treatment options, and personalized medicine approaches to improve early detection and patient outcomes.
    Key Market Dynamics   The key market dynamics for the transient ischemic attack (TIA) market include increasing incidence rates, advances in diagnostic and therapeutic technologies, growing awareness and early intervention, and substantial investment in research and development.

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

    Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

    How much is the global transient ischemic attack market worth in the future?

    The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

    What are the major tailwinds pushing the growth of the global transient ischemic attack market?

    Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

    Which region holds the largest share in the global transient ischemic attack market?

    North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global transient ischemic attack market?

    EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

    1. '1 Report Prologue
    2. Executive Summary
    3. Market Introduction
      1. Definition 26
      2. Scope Of Study
      3. List Of Assumptions 26
      4. Market Structure 27
    4. Research Methodology
      1. Research Process 29
      2. Primary
    5. Research 30
      1. Secondary Research 31
      2. Market Size Estimation
      3. Forecast Model 32
    6. Market Dynamics
    7. Introduction 34
      1. Drivers 35
        1. Increasing Preference
    8. For Minimally Invasive Procedures 35
      1. Rising Prevalence Of Chronic
    9. Disorders 36
      1. Improvement In Reimbursement Scenario 37
        1. Rising Geriatric Population 38
      2. Restraints 39
    10. Rising Treatment Cost And Hospital Stay 39
      1. Lack Of Skilled Physicians
      2. Opportunities 41
        1. New Advancements In Catheterization
    11. Devices 41
      1. Guide Wire Assisted Surgery In Elderly Population 41
      2. Mega Trends 41
        1. Telemedicine 41
      3. Macroeconomic
    12. Indicators 41
      1. Technology Trends & Assessment 42
    13. Market Factor Analysis
      1. Porter’s Five Forces Model 44
        1. Threat Of New Entrants 44
        2. Bargaining Power Of Suppliers
        3. Threat Of Substitutes 45
        4. Bargaining Power Of
    14. Buyers 45
      1. Intensity Of Rivalry 45
      2. Supply Chain Analysis
        1. Research &Development 46
        2. Manufacturing
        3. Distribution 46
        4. Marketing & Sales 47
        5. Post-Sales Monitoring 47
      3. Demand & Supply: Gap Analysis
      4. Pricing Analysis 47
      5. Investment Feasibility Analysis
    15. Global Transient Ischemic Attack Market, By Diagnosis
    16. Introduction 49
      1. Imaging Techniques 49
        1. Computed Tomography
    17. (CT) Scan 51
      1. Carotid Duplex Scanning 51
        1. Magnetic
    18. Resonance Imaging 52
      1. Echocardiography 52
    19. Global Transient
    20. Ischemic Attack Market, By Treatment
      1. Introduction 54
    21. Surgery 54
      1. Drugs 54
        1. Surgery 55
    22. Drugs 56
      1. Antithrombotic Agents 56
        1. Antiplatelets
    23. Heparins 57
      1. ENOXAPARIN 58
        1. DALTEPARIN 58
    24. Alteplase 59
      1. Antihypertensive Agents 59
    25. Prazosin 60
      1. Moxonidine 60
    26. Global Transient Ischemic
    27. Attack Market, By Age Groups
      1. Introduction 62
    28. Years 62
      1. 19–40 Years (Millennial) 62
    29. Years 62
      1. 60+ Years 63
        1. 0-18 Years 64
    30. 40 Years 65
      1. 41-60 Years 65
        1. 60+ Years 65
    31. Global Transient Ischemic Attack Market, By End-User
    32. Introduction 67
      1. Hospitals & Clinics 67
      2. Diagnostic
    33. Centers 67
      1. Research Laboratories 68
        1. Hospitals
        2. Diagnostic Centers 70
        3. Research Laboratories
    34. Global Transient Ischemic Attack Market, By Region
    35. Introduction 72
      1. Americas 73
        1. North America 78
        2. South America
      2. Europe 94
        1. Western Europe
    36. U.K. 111
      1. Italy 115
        1. Spain 119
    37. Rest Of Western Europe 123
      1. Eastern Europe 127
    38. Asia Pacific 131
      1. Asia Pacific 132
        1. Japan 136
        2. China 140
        3. India 144
        4. Australia
        5. Republic Of Korea 152
        6. Rest Of Asia Pacific
      2. The Middle East & Africa 160
        1. Middle East
    39. And Africa 161
      1. United Arab Emirates 164
        1. Saudi
    40. Arabia 168
      1. Rest Of Middle East & Africa 172
    41. Competitive Landscape
      1. Company Market Share Analysis 177
        1. Introduction 177
      2. Company Share Analysis 178
    42. Recent Developments, 2013–2018 179
    43. Company Profiles
      1. Koninklijke Philips N.V. 184
        1. Company Overview 184
        2. Financial Overview 184
        3. Products Offering 185
        4. Key Developments 185
        5. SWOT Analysis 185
    44. Key Strategy 186
      1. Stryker Corporation 187
        1. Company
    45. Overview 187
      1. Financial Overview 187
        1. Products
    46. Offering 188
      1. Key Developments 188
        1. SWOT Analysis
        2. Key Strategy 189
      2. Johnson & Johnson Services
    47. Inc. 190
      1. Company Overview 190
        1. Financial Overview
        2. Products Offering 191
        3. Key Developments 191
        4. SWOT Analysis 192
        5. Key Strategy 192
    48. Boston Scientific Corporation 193
      1. Company Overview 193
        1. Financial Overview 193
        2. Products Offering 194
        3. Key Developments 195
        4. SWOT Analysis 195
    49. Key Strategy 195
      1. Sanofi 196
        1. Company Overview 196
        2. Financial Overview 196
        3. Products Offering 197
        4. Key Developments 197
        5. SWOT Analysis 197
        6. Key Strategy 197
      2. Bayer AG 198
        1. Company
    50. Overview 198
      1. Financial Overview 198
        1. Products
    51. Offering 199
      1. Key Developments 199
        1. SWOT Analysis
        2. Key Strategy 199
      2. Pfizer Inc. 200
        1. Company Overview 200
        2. Financial Overview 200
        3. Products Offering 201
        4. Key Developments 201
    52. SWOT Analysis 201
      1. Key Strategy 201
      2. Siemens AG
        1. Company Overview 202
        2. Financial Overview
        3. Products Offering 203
        4. Key Developments 203
        5. SWOT Analysis 203
        6. Key Strategy 203
    53. F. Hoffmann-La Roche AG 204
      1. Company Overview 204
    54. Financial Overview 204
      1. Products Offering 205
    55. Key Developments 205
      1. SWOT Analysis 205
        1. Key Strategy
      2. GE Healthcare 206
        1. Company Overview 206
        2. Financial Overview 206
        3. Products Offering 207
        4. Key Developments 207
        5. SWOT Analysis 207
        6. Key Strategy 207
      3. Penumbra, Inc. 208
    56. Company Overview 208
      1. Financial Overview 208
    57. Products Offering 209
      1. Key Developments 209
    58. SWOT Analysis 209
      1. Key Strategy 210
      2. Medtronic
    59. PLC 211
      1. Company Overview 211
        1. Financial Overview
        2. Products Offering 212
        3. Key Developments
        4. SWOT Analysis 212
        5. Key Strategy 213
      2. Abbott Laboratories 214
        1. Company Overview 214
        2. Financial Overview 214
        3. Products Offering 215
        4. Key Developments 215
        5. SWOT Analysis 216
        6. Key Strategy 216
      3. Merck & Co., Inc. 217
    60. Company Overview 217
      1. Financial Overview 217
    61. Products Offering 218
      1. Key Developments 218
    62. SWOT Analysis 218
      1. Key Strategy 218
      2. Boehringer
    63. Ingelheim GmbH 219
      1. Company Overview 219
        1. Financial
    64. Overview 219
      1. Products Offering 220
        1. Key Developments
        2. SWOT Analysis 220
        3. Key Strategy 220
    65. Conclusion
      1. Key Findings 222
        1. CEO’s
    66. Viewpoint 222
      1. Unmet Needs 222
        1. Key Companies
    67. To Watch 222
      1. Prediction 222
    68. Appendix
    69. Discussion Blue Print 224
      1. References 225
    70. List Of Tables
    71. ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50
    72. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027
    73. (USD MILLION) 50
    74. IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,
    75. (USD MILLION) 51
    76. IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,
    77. –2027 (USD
    78. MILLION) 51
    79. TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,
    80. –2027 (USD MILLION)
    81. BY ECHOCARDIOGRAPHY,
    82. –2027 (USD MILLION) 52
    83. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION)
    84. SURGERY, 2020–2027 (USD MILLION) 55
    85. ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56
    86. –2027 (USD MILLION) 56
    87. MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    88. –2027 (USD
    89. MILLION) 56
    90. BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57
    91. ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION)
    92. AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57
    93. TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD
    94. MILLION) 58
    95. BY DALTEPARIN, 2020–2027 (USD MILLION) 58
    96. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    97. (USD MILLION) 58
    98. FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59
    99. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027
    100. (USD MILLION) 59
    101. DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59
    102. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,
    103. –2027 (USD MILLION) 60
    104. ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,
    105. (USD MILLION) 60
    106. AGE GROUPS, 2020–2027 (USD MILLION) 63
    107. ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION)
    108. 40 YEARS, 2020–2027 (USD MILLION) 65
    109. ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION)
    110. + YEARS, 2020–2027 (USD MILLION) 65
    111. ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68
    112. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027
    113. (USD MILLION) 69
    114. DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70
    115. GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION,
    116. –2027 (USD MILLION) 70
    117. MARKET, BY REGION, 2020–2027 (USD MILLION) 72
    118. TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73
    119. (USD MILLION) 74
    120. DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74
    121. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD
    122. MILLION) 74
    123. BY DRUGS, 2020–2027 (USD MILLION) 75
    124. ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD
    125. MILLION) 75
    126. AGENTS, BY ANTIPLATELETS,
    127. –2027 (USD MILLION) 75
    128. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
    129. –2027 (USD MILLION) 76
    130. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    131. (USD MILLION) 76
    132. DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76
    133. AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD
    134. MILLION) 77
    135. –2027 (USD MILLION) 77
    136. ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78
    137. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
    138. BY IMAGING TECHNIQUE,
    139. –2027 (USD MILLION) 79
    140. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027
    141. (USD MILLION) 79
    142. FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79
    143. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
    144. –2027 (USD MILLION) 80
    145. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    146. (USD MILLION) 80
    147. FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
    148. –2027 (USD MILLION)
    149. AGENTS, BY FIBRINOLYTICS,
    150. –2027 (USD MILLION) 81
    151. NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    152. AGENTS,
    153. –2027 (USD MILLION) 81
    154. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81
    155. (USD MILLION) 82
    156. –2027 (USD MILLION) 82
    157. MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82
    158. (USD MILLION) 83
    159. BY DRUGS, 2020–2027 (USD MILLION) 83
    160. ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION)
    161. AGENTS, BY ANTIPLATELETS,
    162. –2027 (USD MILLION) 84
    163. U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
    164. –2027 (USD MILLION) 84
    165. MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    166. –2027 (USD
    167. MILLION) 84
    168. BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85
    169. U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
    170. (USD MILLION) 85
    171. DIAGNOSIS, 2020–2027 (USD MILLION) 86
    172. ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
    173. MILLION) 86
    174. –2027 (USD MILLION) 86
    175. MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87
    176. CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
    177. –2027 (USD MILLION) 87
    178. MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    179. –2027 (USD
    180. MILLION) 87
    181. AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88
    182. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    183. –2027 (USD MILLION) 88
    184. ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
    185. (USD MILLION) 89
    186. END-USER, 2020–2027 (USD MILLION) 89
    187. ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90
    188. TECHNIQUE,
    189. –2027 (USD MILLION) 90
    190. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
    191. BY DRUGS, 2020–2027 (USD MILLION) 91
    192. ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
    193. (USD MILLION) 91
    194. FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    195. –2027 (USD MILLION)
    196. AGENTS, BY HEPARINS,
    197. –2027 (USD MILLION) 92
    198. SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY
    199. FIBRINOLYTICS,
    200. –2027 (USD MILLION) 92
    201. AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,
    202. –2027 (USD MILLION) 92
    203. ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93
    204. (USD MILLION) 93
    205. COUNTRY, 2020–2027 (USD MILLION) 94
    206. ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95
    207. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027
    208. (USD MILLION) 95
    209. TREATMENT,, 2020–2027 (USD MILLION) 95
    210. ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96
    211. AGENTS, 2020–2027 (USD MILLION) 96
    212. ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    213. (USD MILLION) 96
    214. ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97
    215. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    216. –2027 (USD MILLION) 97
    217. ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
    218. (USD MILLION) 98
    219. END-USER, 2020–2027 (USD MILLION) 98
    220. ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99
    221. TECHNIQUE,
    222. –2027 (USD MILLION) 99
    223. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
    224. BY DRUGS, 2020–2027 (USD MILLION) 100
    225. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,
    226. (USD MILLION) 100
    227. MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    228. –2027 (USD
    229. MILLION) 100
    230. FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
    231. –2027 (USD MILLION)
    232. AGENTS, BY FIBRINOLYTICS,
    233. –2027 (USD MILLION) 101
    234. AGENTS,
    235. –2027 (USD MILLION) 101
    236. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
    237. –2027 (USD MILLION) 102
    238. ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103
    239. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
    240. –2027 (USD MILLION) 103
    241. ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103
    242. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027
    243. (USD MILLION) 104
    244. FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104
    245. BY ANTIPLATELETS,
    246. –2027 (USD MILLION) 104
    247. GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,
    248. –2027 (USD MILLION) 105
    249. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    250. (USD MILLION) 105
    251. FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105
    252. (USD MILLION) 106
    253. BY END-USER, 2020–2027 (USD MILLION) 106
    254. ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107
    255. –2027 (USD MILLION) 107
    256. ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107
    257. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027
    258. (USD MILLION) 108
    259. DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108
    260. FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    261. –2027 (USD MILLION) 108
    262. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD
    263. MILLION) 109
    264. AGENTS, BY FIBRINOLYTICS,
    265. –2027 (USD MILLION) 109
    266. AGENTS, 2020–2027 (USD MILLION) 109
    267. ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110
    268. (USD MILLION) 110
    269. DIAGNOSIS, 2020–2027 (USD MILLION) 111
    270. ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
    271. MILLION) 111
    272. –2027 (USD MILLION) 111
    273. MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112
    274. U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027
    275. (USD MILLION) 112
    276. ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112
    277. –2027 (USD MILLION) 113
    278. MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION)
    279. AGENTS, 2020–2027 (USD MILLION) 113
    280. ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114
    281. U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION)
    282. (USD MILLION) 115
    283. DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115
    284. ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION)
    285. DRUGS, 2020–2027 (USD MILLION) 116
    286. ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION)
    287. AGENTS, BY ANTIPLATELETS,
    288. –2027 (USD MILLION) 116
    289. HEPARINS, 2020–2027 (USD MILLION) 117
    290. ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    291. (USD MILLION) 117
    292. DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117
    293. ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION)
    294. (USD MILLION) 118
    295. DIAGNOSIS, 2020–2027 (USD MILLION) 119
    296. ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD
    297. MILLION) 119
    298. –2027 (USD MILLION) 119
    299. ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120
    300. AGENTS, 2020–2027 (USD MILLION) 120
    301. ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,
    302. (USD MILLION) 120
    303. ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121
    304. SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,
    305. –2027 (USD MILLION) 121
    306. ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION)
    307. (USD MILLION) 122
    308. END-USER, 2020–2027 (USD MILLION) 122
    309. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
    310. FOR DIAGNOSIS, BY IMAGING TECHNIQUE,
    311. –2027 (USD MILLION) 123
    312. –2027 (USD MILLION) 123
    313. ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124
    314. BY ANTITHROMBOTIC AGENTS,
    315. –2027 (USD MILLION) 124
    316. AGENTS, BY ANTIPLATELETS,
    317. –2027 (USD MILLION) 124
    318. AGENTS, BY HEPARINS,
    319. –2027 (USD MILLION) 125
    320. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS,
    321. BY FIBRINOLYTICS,
    322. –2027 (USD MILLION) 125
    323. REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE
    324. AGENTS,
    325. –2027 (USD MILLION) 125
    326. WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD
    327. MILLION) 126
    328. MARKET, BY END-USER, 2020–2027 (USD MILLION) 126
    329. EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION)
    330. BY IMAGING TECHNIQUE,
    331. –2027 (USD MILLION) 127
    332. EASTERN EUROPE TRANSIENT ISCHE'

    Transient Ischemic Attack Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Transient Ischemic Attack Market Research Report - Global Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027